Omega Therapeutics, Inc. (OMGA) Misses Q2 EPS by 4c

Omega Therapeutics, Inc. (NASDAQ: OMGA) reported Q2 EPS of ($0.54), $0.04 worse than the analyst estimate of ($0.50). Revenue for the quarter came in at $760 thousand versus the consensus estimate of $378.57 thousand.

For earnings history and earnings-related data on Omega Therapeutics, Inc. (OMGA) click here.

You May Also Be Interested In

• Valens Semiconductor (VLN) Reports In-Line Q2 EPS, Misses on Revenue; Offers FY26 Revenue Guidance
• Aardvark Therapeutics (AARD) Tops Q2 EPS by 21c
• New York City REIT Inc. (NYC) Reports Q2 Loss of $3.04